The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia
Status:
Terminated
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The present study will specify and delineate the separate components of cognitive deficits
and examine the effects of adjunctive cholinergic augmentation on these cognitive deficits as
well as psychopathology in schizophrenic patients treated with an antipsychotic compound with
no aberrant binding affinity for the cholinergic receptor system. The hypothesis is that
cholinergic augmentation using donepezil will improve cognitive deficits, sensory gating
deficits, and psychopathology in schizophrenic patients treated with an atypical
antipsychotic (ziprasidone).
Phase:
Phase 2
Details
Lead Sponsor:
Birte Glenthoj
Collaborators:
Glostrup University Hospital, Copenhagen Pfizer Rigshospitalet, Denmark